EGFR lung cancer refers to non-small cell lung cancer (NSCLC) driven by mutations in the epidermal growth factor receptor gene. About 10% to 50% of NSCLC cases carry an EGFR mutation, depending on ethnicity and smoking history. These mutations cause cells to grow and divide uncontrollably, but they also create a specific vulnerability: targeted drugs can block the faulty protein and slow the cancer’s progression far more precisely than traditional chemotherapy.
How EGFR Mutations Drive Cancer Growth
EGFR is a protein that sits on the surface of cells and acts like a switch for growth signals. In healthy tissue, the switch turns on and off as needed. When certain mutations occur in the EGFR gene, the switch gets stuck in the “on” position. This triggers a cascade of internal signals that tell the cell to keep dividing, avoid normal cell death, and form tumors.
The mutations responsible occur in a specific region of the gene (exons 18 through 21) and supercharge the protein’s activity. Three main signaling chains get hijacked: one that drives cell multiplication, one that promotes cell survival, and one that fuels inflammation. Together, these pathways give cancer cells a powerful growth advantage over normal tissue.
Who Gets EGFR-Positive Lung Cancer
EGFR mutations are far more common in certain groups. Ethnicity plays the biggest role: 40% to 50% of Asian patients with NSCLC carry an EGFR mutation, compared with roughly 10% of Caucasian patients. Taiwan has reported rates as high as 55%, while North America sits around 9%.
People who have never smoked are about three times more likely to have an EGFR mutation than current smokers (31% vs. 10% in large studies). Women are also significantly more affected than men (about 30% vs. 6%). The mutation is most commonly found in adenocarcinoma, the most prevalent subtype of NSCLC, where it appears in roughly 19% of cases compared with about 7% of other subtypes. This is one reason lung cancer screening and molecular testing matter even for people without a smoking history.
The Most Common Mutation Types
Two mutations account for the vast majority of EGFR-positive cases. Exon 19 deletions involve a small piece of genetic code being removed, while the L858R point mutation in exon 21 swaps one amino acid for another. Both produce the same basic effect: an overactive growth signal. These are considered “classic” or “sensitizing” mutations because they respond well to targeted therapy.
Less common variants include S768I, L861Q, G719X, and exon 20 insertions. Exon 20 insertions are particularly notable because they don’t respond to the same drugs that work against the classic mutations, and they require a different treatment approach.
How EGFR Mutations Are Detected
Every patient diagnosed with advanced NSCLC should have their tumor tested for EGFR mutations, because the result determines which treatment will work best. There are two main testing methods.
Tissue biopsy remains the gold standard. A small sample of tumor is analyzed for genetic changes across multiple cancer-related genes. The alternative is a liquid biopsy, which detects fragments of tumor DNA circulating in the bloodstream. The FDA approved the first liquid biopsy test for EGFR mutations in 2016, and for most patients, liquid biopsy results are consistent with tissue biopsy results. However, liquid biopsies can miss mutations (a false negative), so a negative blood test should be followed up with a tissue biopsy to be sure. In practice, many oncologists use both: tissue biopsy for the initial diagnosis and liquid biopsy later to track how the cancer responds to treatment or develops resistance.
Targeted Treatment Options
The backbone of EGFR-positive lung cancer treatment is a class of drugs called tyrosine kinase inhibitors, or TKIs. These pills block the overactive EGFR protein directly, cutting off the growth signals that fuel the tumor. Three generations of TKIs now exist:
- First generation (gefitinib, erlotinib): The earliest targeted options, which reversibly block the EGFR protein.
- Second generation (afatinib, dacomitinib): These bind more tightly and permanently to EGFR, producing somewhat longer periods before the cancer progresses.
- Third generation (osimertinib): Currently the preferred first-line treatment. Osimertinib was designed to work against both the original activating mutations and a common resistance mutation that defeats earlier drugs.
For the classic exon 19 deletion or L858R mutation, the National Comprehensive Cancer Network recommends osimertinib as the preferred first-line option. The other TKIs remain recommended alternatives. Combination regimens pairing osimertinib with chemotherapy are also now listed as options for first-line treatment of nonsquamous disease.
For less common mutations like S768I, L861Q, or G719X, afatinib or osimertinib are the preferred choices. Exon 20 insertions require a different strategy entirely: a combination of amivantamab (a bispecific antibody) with chemotherapy is the current preferred first-line approach for those patients.
Why Resistance Develops
Nearly all patients on targeted therapy will eventually see their cancer start growing again, typically after months to a couple of years. The cancer cells acquire new mutations that prevent the drug from binding to its target.
The most well-known resistance mechanism is the T790M mutation, which blocks first- and second-generation TKIs from reaching their binding site on the EGFR protein. This is precisely why osimertinib was developed: it forms a different kind of bond with the protein that bypasses the T790M roadblock.
But resistance to osimertinib itself also occurs. The most common escape route is the C797S mutation, which changes the specific spot where osimertinib latches onto the protein. This accounts for 7% to 26% of resistance cases, depending on whether osimertinib was used as first-line or second-line treatment. Other resistance mechanisms include amplification of alternative growth pathways or, in rare cases, transformation of the cancer into a different cell type entirely. When resistance emerges, oncologists typically repeat molecular testing (often via liquid biopsy) to identify the specific mechanism and guide the next treatment choice.
Side Effects of EGFR-Targeted Therapy
TKIs are significantly less toxic than traditional chemotherapy, but they do cause predictable side effects. Because the EGFR protein is naturally active in skin and gut cells, those are the areas most affected.
Skin reactions are the most common issue, occurring in more than half of patients. The hallmark is an acne-like rash of small bumps and pustules, typically on the face, scalp, upper chest, and back. This appears in 37% to 78% of patients in clinical trials and tends to be dose-related. About 35% of patients also develop dry, itchy skin on the arms and legs, which can occasionally become infected. Nail changes, hair thinning, and hand and foot reactions also occur.
Diarrhea is the other major side effect, affecting 27% to 87% of patients depending on the specific drug. It results from the drug disrupting chloride balance in the intestinal lining, causing excess fluid secretion. Most cases are mild to moderate, but up to 25% of patients experience severe episodes that may require dose adjustments. Both the rash and diarrhea are generally manageable with supportive care, and many patients find these side effects improve or stabilize over the first few months of treatment.
Survival and Outlook
Having an EGFR mutation in lung cancer is, in one important sense, fortunate: it means effective targeted therapies are available. Patients with EGFR-positive NSCLC treated with TKIs consistently live longer than those without a targetable mutation who rely on chemotherapy alone.
That said, outcomes depend heavily on stage at diagnosis. Roughly 70% of patients with EGFR mutations are diagnosed with distant metastases, and five-year survival for that group remains around 11%. For earlier-stage disease, the picture is considerably better, and osimertinib has also been approved as a post-surgery treatment to reduce the risk of recurrence.
Treatment options continue to expand. A recent phase 3 trial published in the New England Journal of Medicine found that a combination of amivantamab and lazertinib significantly improved progression-free survival compared with osimertinib alone as first-line therapy for EGFR-mutated advanced NSCLC. These newer combinations represent a shift toward hitting EGFR-driven cancers from multiple angles simultaneously, aiming to delay resistance and extend survival further.